Eli Lilly and Company continues to dominate headlines in the pharmaceutical industry, thanks to its robust pipeline, blockbuster drugs, and bold strategic moves in 2025. From record-breaking sales of its incretin therapies to ambitious manufacturing expansions and cutting-edge acquisitions, Eli Lilly and Company is setting the pace for innovation and growth in global healthcare. Over … Continue reading Eli Lilly and Company: Latest Developments and 2025 Outlook